First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors

被引：8

作者：

Azari, Arianna E. ^{[1
,2
]}

Stratton, Richard ^{[1
,2
]}

Singh, Animesh ^{[1
,2
]}

机构：

[1] Royal Free Hosp, Ctr Rheumatol, London, England

[2] UCL, Sch Med, London, England

来源：

RHEUMATOLOGY | 2021年 / 60卷 / 05期

关键词：

D O I：

10.1093/rheumatology/keaa750

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E167 / E168

页数：2

共 4 条

[1] Sorting Out the Complexities of Autoimmunity and Checkpoint Inhibitors: Not So Easy [J].

Calabrese, Leonard H. .

ANNALS OF INTERNAL MEDICINE, 2018, 168 (02) :149-150

[2] Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa [J].

Khan, Kabir A. ;

Kerbel, Robert S. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (05) :310-324

[3] Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth [J].

Yakes, F. Michael ;

Chen, Jason ;

Tan, Jenny ;

Yamaguchi, Kyoko ;

Shi, Yongchang ;

Yu, Peiwen ;

Qian, Fawn ;

Chu, Felix ;

Bentzien, Frauke ;

Cancilla, Belinda ;

Orf, Jessica ;

You, Andrew ;

Laird, A. Douglas ;

Engst, Stefan ;

Lee, Lillian ;

Lesch, Justin ;

Chou, Yu-Chien ;

Joly, Alison H. .

MOLECULAR CANCER THERAPEUTICS, 2011, 10 (12) :2298-2308

[4] Targeting veGF/veGFR to Modulate Antitumor immunity [J].

Yang, Ju ;

Yan, Jing ;

Liu, Baorui .

FRONTIERS IN IMMUNOLOGY, 2018, 9

← 1 →